Establishment of Optimal Transfusion Threshold After Major Orthopedic Surgery
This study has been completed.
Sponsor:
Rigshospitalet, Denmark
Collaborator:
TrygFonden, Denmark
Information provided by:
Rigshospitalet, Denmark
ClinicalTrials.gov Identifier:
NCT00906295
First received: May 20, 2009
Last updated: June 3, 2011
Last verified: June 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether a higher threshold for transfusion with red blood cells improves the postoperative ambulation.
| Condition | Intervention |
|---|---|
|
Anemia Arthroplasty Replacement Hip |
Other: Allowed drop in hemoglobin to 4.5-5.5 mmol/L Other: Allowed drop in hemoglobin to level between 5.6-6.5 mmol/L |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Establishment of Optimal Transfusion Threshold After Major Orthopedic Surgery |
Resource links provided by NLM:
Further study details as provided by Rigshospitalet, Denmark:
Primary Outcome Measures:
- Timed Up and Go-test (TUG)in seconds. [ Time Frame: 30 days ] [ Designated as safety issue: No ]Timed Up and Go-test is performed when the patient is able to undertake the test after surgery. This is judged by a physiotherapist. The test measures how long it takes the patient to rise, walk 3 meters, turn around, walk back and sit down again.
Secondary Outcome Measures:
- The postoperative day patients can walk ten meters [ Time Frame: 30 days ] [ Designated as safety issue: No ]
- Length of stay at hospital [ Time Frame: 30 days ] [ Designated as safety issue: No ]
- The day the patient is able to perform Timed Up and Go-test [ Time Frame: 30 days ] [ Designated as safety issue: No ]
| Enrollment: | 67 |
| Study Start Date: | June 2009 |
| Study Completion Date: | June 2011 |
| Primary Completion Date: | May 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Allowed drop in hemoglobin to 4.5-5.5 mmol/L
Transfusion with red blood cells to level between 4.5-5.5 mmol/L
|
Other: Allowed drop in hemoglobin to 4.5-5.5 mmol/L
Transfusion with red blood cells to hemoglobin between 4.5-5.5 mmol/L (Transfusion threshold of 4.5 mmol/L)
|
|
Experimental: Allowed drop in hemoglobin to 5.6-6.5 mmol/L
Transfusion with red blood cells to level between 5.6-6.5 mmol/L
|
Other: Allowed drop in hemoglobin to level between 5.6-6.5 mmol/L
Transfusion with red blood cells to between hemoglobin 5.6-6.5 mmol/L (Transfusion threshold of 5.5 mmol/L)
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- 18 years or older
- Patients undergoing replacement of hip arthroplasty
- Be legally competent
- Read and understand Danish
Exclusion Criteria:
- Present malignant disease
- Known heart disease with functionality equivalent to NYHA II or CCS II or worse
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00906295
Locations
| Denmark | |
| Bispebjerg Hospital | |
| Copenhagen, Copenhagen NV, Denmark, 2400 | |
| Copenhagen University Hospital, Rigshospitalet | |
| Copenhagen, Østerbro, Denmark, 2100 | |
Sponsors and Collaborators
Rigshospitalet, Denmark
TrygFonden, Denmark
Investigators
| Principal Investigator: | Kamilla Nielsen, MD | Rigshospitalet, Denmark |
More Information
Additional Information:
No publications provided
| Responsible Party: | MD Kamilla Nielsen, Rigshospitalet |
| ClinicalTrials.gov Identifier: | NCT00906295 History of Changes |
| Other Study ID Numbers: | H-D-2009-024 |
| Study First Received: | May 20, 2009 |
| Last Updated: | June 3, 2011 |
| Health Authority: | Denmark: Ethics Committee |
Keywords provided by Rigshospitalet, Denmark:
|
Hemoglobin Ambulation |
Additional relevant MeSH terms:
|
Anemia Hematologic Diseases |
ClinicalTrials.gov processed this record on May 16, 2013